Home > Healthcare & Medical Devices > Microcarrier Market
Microcarrier Market Size is projected to showcase promising growth from 2022 to 2028. The growing incidence of chronic ailments across the globe is anticipated to positively affect the use of microcarriers. Microcarriers offer a larger surface area as compared to the standard tissue culture plastics. They play an important role in increasing the cell population, which can help researchers in developing a wide range of medicines. One of the main uses of microcarriers includes the production of vaccines.
Governments across the world are increasing their investments in different types of healthcare research and are encouraging companies to amplify their research and development activities to leverage advanced technologies in cell therapy. For example, in 2021, the Department of Health of the government of Australia developed a research funding program, ‘Stem Cell Therapy Mission’ that will make an investment of $150 million over the next 9 years to create high-quality, innovative, safe, and accessible stem cell treatments for Australian citizens. Such initiatives are anticipated to foster the use of microcarriers.
In terms of the product, the demand for microcarrier consumables is expected to grow at a significant rate across many regions to help companies produce innovative animal as well as human health products. Organizations like Sartorius, for example, have created animal protein-coated and animal product-free microcarriers, named SoloHill. The consumables can be highly used for any type of process wherein the capital investment and the timelines given to develop a process are limited.
Vaccine manufacturing segment, in terms of the application spectrum, will be in high demand across the globe due to the growing cases of chronic disorders. The COVID-19 pandemic played an important role in skyrocketing the production of vaccines to combat the virus. In recent years, the cases of infectious diseases have gone up due to massive growth in pollution level, lack of access to clean drinking water in rural areas, and decreased physical activity in cities, which negatively affects the immunity system. Moreover, the percentage of the elderly population is rising at a notable rate across regions, such as Asia Pacific and Europe and it is more susceptible to contracting deadly viruses, further augmenting the production of vaccines.
With respect to the end-use segment, research institutes will increasingly use microcarriers to experiment with and develop a variety of medicines and vaccines and help patients combat fatal diseases. Sometimes, researchers require sufficient surface area and a higher cell population to help them conduct a deeper analysis while developing cell therapies. In such a case, microcarriers are highly used as they offer a larger surface area and can help in expanding the cell population.
For example, in November 2020, researchers of Singapore-MIT Alliance for Research and Technology (SMART) came together to develop a new dissolvable gelatin-based microcarrier that can aid in the large-scale production and expansion of cells. The microcarrier is a cost-effective yet higher yield alternative to the traditional methods, which will be key to amplifying its demand.
North America is projected to hold a substantial share of microcarrier market during the forecast period of 2022-2028. The region has some of the best healthcare companies and facilities along with highly trained medical professionals.
Governments across the region are boosting their investments to help the healthcare sector grow and are also offering financial backing to a wide range of cell therapy researches so that people can have easier access to advanced medical facilities. Medical scientists in the region are developing several cell therapies to create vaccines and medicines, thereby increasing the adoption of microcarriers.
Prominent companies involved in the production of microcarriers include, Sartorius, Lonza, Becton, Dickinson and Company, Corning Incorporated, Thermo Fisher Scientific, Merck, GE Healthcare, HiMedia Laboratories, Danaher Corporation, and Eppendorf, among others. The organizations are developing a variety of business strategies to strengthen their market presence and expand their customer base across regions.
For instance, Thermo Fisher Scientific, in December 2020, announced the construction of a new cGMP plasmid DNA manufacturing plant in Carlsbad, California. The aim behind opening a new facility is to increase the commercial and clinical capabilities for cGMP plasmid DNA, which is commonly used as a raw material to create cell and gene therapies, such as mRNA vaccines and effective cancer treatments. The strategic move will help the organization extend its footprint in the U.S. and Europe.
The COVID-19 pandemic played a vital role in bolstering the adoption of microcarriers as there was a booming demand for vaccines to fight the virus. A large number of research institutes and laboratories significantly increased their research and development activities to conduct various experiments and find viable solutions to contain the spread of the virus.
Market, By Product
Market, By Application
Market, By End-use
The above information is provided for the following regions and countries: